Savient sells gout med to Crealta

The $120.4-million deal is part of Savient's bankruptcy auction.

December 11, 2013

8:07 pm

Pending court approval, Savient’s orphan drug Krystexxa will join Crealta Pharmaceuticals’ drug portfolio.

Savient announced the deal for its refractory chronic gout medication Wednesday.

The $120.4-million sale is part of a bankruptcy auction. The companies expect the court to weigh in on Friday.

From Our Partners

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

Partner Content

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

The evolution of patient needs and rising consumer expectations are shaping a new era in healthcare — one that calls for a paradigm shift in the pharmaceutical industry's approach to patient support.

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.